Predictors of recurrence in remitted late-life depression

cumulative illness rating scale severity index

ratio HR=1.536 confidence interval CI=1.027-2.297
(4) Mini Mental State Examination MMSE score<25; (5

Finding factors that predict treatment-resistant depression: Results of a cohort study

RR=1.42, 95% confidence interval CI 1.37-1.48

Familial aggregation of major depressive disorder in an African-American community

OR=1.2, 95% confidence interval CI=0.5-2.9
adjusted OR=2.8, 95% confidence interval CI=1.10-7.10

Cognitive performance in antidepressant-free recurrent major depressive disorder

Maternal depressive symptoms during and after pregnancy and child developmental milestones

unstandardized regression coefficient of tobit regression

mean=2.41 weeks postpartum standard deviation SD=1.2; range:0.1-18.0
mean=28.3 weeks postpartum; SD=4.2; range:18.4-54.3

Cortical thickness and white matter integrity abnormalities in obsessive-compulsive disorder: A combined multimodal surface-based morphometry and tract-based spatial statistics study

two tailed pearson partial correlation analysis
threshold of cortical thickness analysis

echoing TE=2500/80 ms, slice thickness=6
TR/TE=7.38/3.4 ms, slice thickness=1.2 mm, FOV=250 mm*250 mm, matrix size=256*256, flip angle=90◦, slices=230
TR/TE=6800 ms/80 ms, matrix size=116*112, voxel size=1.98 mm*2.05 mm*3 mm, b=1000 s/mm2, slice thickness=3 mm, FOV=230 mm2*230 mm2, flip angle=90

Error-related brain activity in adolescents with obsessive-compulsive disorder and major depressive disorder

Personal sleep debt and daytime sleepiness mediate the relationship between sleep and mental health outcomes in young adults

depression scores gad 7 anxiety scores variable coefficient
mturk sample persists even if restricting analysis

Effect of insomnia treatments on depression: A systematic review and meta-analysis

Pharmaceuticalot OR<=>5 Hydroxytryptophanmh OR<=>5 Hydroxytryptophantiab OR<=>5
OR "CP 96345"nm OR "CP 96345"tiab OR "CP 96345"ot OR detomidinenm OR detomidinetiab OR detomidineot OR etironnm OR etirontiab OR etironot OR fluanisonenm OR fluanisonetiab OR fluanisoneot OR fospropofolnm OR fospropofoltiab OR fospropofolot OR indiplonnm OR indiplontiab OR indiplonot OR lormetazepamnm OR lormetazepamtiab OR lormetazepamot OR nimetazepamnm OR nimetazepamtiab OR nimetazepamot OR oleylamidenm OR oleylamidetiab OR oleylamideot OR phetharbitalnm OR phetharbitaltiab OR phetharbitalot OR proxibarbalnm OR proxibarbaltiab OR proxibarbalot OR quazepamnm OR quazepamtiab OR quazepamot OR remifentanilnm OR remifentaniltiab OR remifentanilot OR rilmazafonenm OR rilmazafonetiab OR rilmazafoneot OR "S 20098"nm OR "S 20098"tiab OR "S 20098"ot OR secbutabarbitalnm OR secbutabarbitaltiab OR secbutabarbitalot OR taglutimidenm OR taglutimidetiab OR taglutimideot OR zaleplonnm OR zaleplontiab OR zaleplonot OR zolpidemnm OR zolpidemtiab OR zolpidemot OR zopiclonenm OR zopiclonetiab OR zopicloneot OR<=>2- 3,4 dimethoxyphenyl -3 fluoroallylaminenm OR<=>2-3,4 dimethoxyphenyl-3 fluoroallyl aminetiab OR<=>2-3,4 dimethoxyphenyl-3 fluoroallylamine OR<=>3 hydroxy-2 oxoindoletiab OR<=>3 hydroxy-2 oxoindoleot OR "3 methoxymethyl-7-(4,4,4 trifluorobutoxy)-3,3a,4,5 OR Serotonin Reuptake Inhibitorsot OR<=>5 HT Uptake Inhibitorstiab OR<=>5 HT Uptake Inhibitorsot OR<=>5 HT Uptake Inhibitorstiab OR<=>5